Stem cells such as mesenchymal stem cells (MSCs) enhance neurological recovery in
preclinical stroke models by secreting extracellular vesicles (EVs). Since previous reports …

Background and Purpose—Recent work from our group suggests that human neural stem
cell–derived extracellular vesicle (NSC EV) treatment improves both tissue and …

Stroke is the leading cause of physical disability among adults. Stem cells such as
mesenchymal stem cells (MSCs) secrete a variety of bioactive substances, including trophic …

Stroke imposes a long‐term neurological disability with limited effective treatments available
for neuronal recovery. Transplantation of neural stem cells (NSCs) is reported to improve …

Stem cell-based treatments have been suggested as promising candidates for stroke.
Recently, mesenchymal stem cells (MSCs) have been reported as potential therapeutics for …

Although the initial concepts of stem cell therapy aimed at replacing lost tissue, more recent
evidence has suggested that stem and progenitor cells alike promote postischemic …

A major clinical hurdle to translate MSC-derived extracellular vesicles (EVs) is the lack of a
method to scale-up the production of EVs with customized therapeutic properties. In this …

Background Mesenchymal stem cell-derived extracellular vesicles (EVs) are one of the most
promising therapeutics in protective and/or regenerative therapy in animal models of stroke …

Despite recent advances in stroke therapy, current therapeutic concepts are still limited.
Thus, additional therapeutic strategies are in order. In this sense, the transplantation of stem …

Background: Stroke represents the second leading cause of death and the primary cause of
long-term disability in humans. The transplantation of mesenchymal stem cells (MSC) …